Skip to main content

Advertisement

Table 2 Main results of pooled ORs and stratification analysis of IRF4 polymorphisms on cancer risk in the meta-analysis

From: Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case–control studies

rs12203592 TT vs CC CT vs CC Dominant model Recessive model Additive model
C/T OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa OR 95% CI Pa
Overall 1.566 (1.087,2.256)* 0.000 1.070 (0.904,1.266)* 0.000 1.135 (0.941,1.368)* 0.000 1.526 (1.107,2.104)* 0.001 1.168 (0.981,1.392)* 0.000
Source of controls
PB 0.933 (0.672,1.295) 0.403 0.904 (0.793,1.031) 0.320 0.907 (0.799,1.029) 0.265 0.971 (0.701,1.345) 0.420 0.926 (0.830,1.033) 0.215
HB 2.094 (1.314,3.336)* 0.000 1.203 (0.936,1.547)* 0.000 1.314 (1.002,1.723)* 0.000 1.959 (1.310,2.931)* 0.003 1.351 (1.058,1.725)* 0.000
Cancer type
Skin cancer 1.808 (1.127,2.900)* 0.000 1.130 (0.890,1.435)* 0.000 1.217 (0.935,1.584)* 0.000 1.728 (1.145,2.608)* 0.000 1.253 (0.983,1.596)* 0.000
Melanoma 1.315 (0.624,2.770)* 0.000 0.957 (0.724,1.265)* 0.009 1.011 (0.715,1.431)* 0.000 1.321 (0.684,2.552)* 0.001 1.057 (0.747,1.497)* 0.000
BCC 2.511 (1.630,3.867) 0.430 1.085 (0.861,1.368) 0.668 1.245 (1.004,1.543) 0.996 2.451 (1.600,3.755) 0.383 1.352 (1.131,1.617) 0.644
SCC 2.520 (1.598,3.974) 0.703 1.651 (1.330,2.049) 0.208 1.743 (1.418,2.143) 0.207 2.120 (1.354,3.318) 0.901 1.643 (1.385,1.949) 0.303
NHL 1.074 (0.734,1.571) 0.677 0.948 (0.820,1.096) 0.545 0.960 (0.834,1.104) 0.734 1.103 (0.756,1.608) 0.589 0.979 (0.867,1.106) 0.914
Ethnicity
Caucasian 1.808 (1.127,2.900)* 0.000 1.130 (0.890,1.435)* 0.000 1.135 (0.941,1.368)* 0.000 1.728 (1.145,2.608)* 0.000 1.253 (0.983,1.596)* 0.000
Mixed 1.074 (0.734,1.571) 0.677 0.948 (0.820,1.096) 0.545 0.960 (0.834,1.104) 0.734 1.103 (0.756,1.608) 0.589 0.979 (0.867,1.106) 0.914
rs872071 GG vs AA GA vs AA Dominant model Recessive model Additive model
G/A OR 95% CI P a OR 95% CI P a OR 95% CI P a OR 95% CI P a OR 95% CI P a
Overall 1.805 (1.402,2.323)* 0.002 1.427 (1.203,1.692)* 0.034 1.556 (1.281,1.891)* 0.003 1.432 (1.293,1.587) 0.109 1.349 (1.201,1.515)* 0.002
Source of controls
PB 1.767 (1.244,2.511)* 0.003 1.369 (1.041,1.801)* 0.018 1.478 (1.278,1.708)* 0.003 1.443 (1.270,1.639) 0.070 1.329 (1.116,1.582)* 0.002
HB 1.884 (1.212,2.930)* 0.037 1.446 (1.247,1.678) 0.255 1.637 (1.219,2.198) 0.058 1.414 (1.191,1.678) 0.215 1.333 (1.213,1.465) 0.069
Cancer type
CLL 2.424 (1.995,2.945) 0.841 1.752 (1.466,2.093) 0.825 1.982 (1.674,2.346) 0.968 1.646 (1.431,1.892) 0.445 1.543 (1.407,1.692) 0.647
Lymphoma 1.396 (1.123,1.735) 0.614 1.279 (1.103,1.483) 0.472 1.308 (1.135,1.507) 0.579 1.245 (1.039,1.491) 0.754 1.206 (1.095,1.328) 0.764
Ethnicity
Caucasian 1.844 (1.377,2.470)* 0.003 1.418 (1.124,1.787)* 0.019 1.567 (1.214,2.023)* 0.003 1.463 (1.311,1.633) 0.115 1.350 (1.174,1.554)* 0.003
Asian 1.451 (1.072,1.965) 0.075 1.380 (1.164,1.636) 0.205 1.390 (1.180,1.637) 0.109 1.233 (0.924,1.646) 0.167 1.256 (1.110,1.420) 0.071
  1. PB: population based; HB: hospital based; Bold data represent the positive results.
  2. *Random-effects model was used when P value for heterogeneity test < 0.05; otherwise, fix-effects model was used.
  3. aP value of Q-test for heterogeneity test; BCC: Basal cell carcinoma; SCC: Squamous cell carcinoma; HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; MM: Multiple myeloma; CLL: Chronic lymphocytic leukaemia.